Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer After Platinum Chemotherapy-Reference-Cited by-同舟云学术

Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer After Platinum Chemotherapy

Published:2019-07 Issue:4 Volume:20 Page:287-296.e4
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Schwartzberg Lee,Korytowsky Beata,Penrod John R.,Zhang Ying,Le T. Kim,Batenchuk Cory,Krug Lee

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Treatment patterns for advanced non–small-cell lung cancer after platinum-containing therapy in U.S. community oncology clinical practice;McKay;Clin Lung Cancer,2016

3. Revisiting stage IIIB and IV non–small-cell lung cancer: analysis of the Surveillance, Epidemiology, and End Results data;William;Chest,2009

4. Lung cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study;Richards;Cancer,2017

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan;JCO Global Oncology;2024-03

2. Simvastatin Enhanced Anti-tumor Effects of Bevacizumab against Lung Adenocarcinoma A549 Cells via Abating HIF-1α-Wnt/β-Catenin Signaling Pathway;Anti-Cancer Agents in Medicinal Chemistry;2023-11

3. Role of high‑sensitivity C‑reactive protein in patients with sarcoma;Oncology Letters;2023-10-30

4. Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors;JTO Clinical and Research Reports;2023-06

5. Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements;BMC Cancer;2023-05-29